Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

1. The EAU – EANM – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer

. Association of male circumcision with risk of prostate cancer: a meta-analysis. Prostate Cancer Prostatic Dis, 2015. 18: 352. 73. Rider, J.R., et al. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol, 2016. 70: 974. 74. Brierley, J.D., et al., TNM classification of malignant tumors. UICC International Union Against Cancer. 8th edn. 2017. 75. Cooperberg, M.R., et al. The University of California, San Francisco Cancer of the Prostate Risk (...) of atypical small acinar proliferation. Can J Urol, 2017. 24: 8714. 219. Epstein, J.I., et al. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol, 2006. 175: 820. 220. Merrimen, J.L., et al. Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J Urol, 2009. 182: 485. 221. Kronz, J.D., et al. High-grade prostatic intraepithelial neoplasia

2020 European Association of Nuclear Medicine

2. Prostate cancer: diagnosis and management

. Ov Overview erview This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer. Who is it for? Healthcare professionals Commissioners and providers of prostate cancer services People with prostate cancer, their families (...) and and that there is limited evidence for some treatment options. [2014] [2014] 1.1.11 Ensure that mechanisms are in place so people with prostate cancer and their primary care providers have access to specialist services throughout the course of their disease. [2008] [2008] 1.1.12 T ell people with prostate cancer and their partners or carers about the effects of prostate cancer and the treatment options on their: sexual function physical appearance continence Prostate cancer: diagnosis and management (NG131) © NICE 2019

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

3. Prostate cancer screening

, prostate biopsy, prostate cancer diagnosis, and definitive local treatment were determined using associated International Classification of Diseases, Ninth Revision and Current Procedural Terminology, Fourth Edition codes. RESULTS: There were approximately 6 million qualifying men with a full year of data. PSA 2018 8. Harms of Prostate -Specific Antigen ( PSA ) screening in prostate cancer : a rapid review Harms of Prostate -Specific Antigen ( PSA ) screening in prostate cancer : a rapid review Harms (...) Prostate cancer screening Top results for prostate cancer screening - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search

2018 Trip Latest and Greatest

4. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. (Abstract)

Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Multiparametric magnetic resonance imaging (MRI), with or without MRI-targeted biopsy, is an alternative test to systematic transrectal ultrasonography-guided biopsy in men suspected of having prostate cancer. At present, evidence on which test to use is insufficient to inform detailed evidence-based decision-making.To determine the diagnostic accuracy of the index tests MRI only, MRI (...) -targeted biopsy, the MRI pathway (MRI with or without MRI-targeted biopsy) and systematic biopsy as compared to template-guided biopsy as the reference standard in detecting clinically significant prostate cancer as the target condition, defined as International Society of Urological Pathology (ISUP) grade 2 or higher. Secondary target conditions were the detection of grade 1 and grade 3 or higher-grade prostate cancer, and a potential change in the number of biopsy procedures.We performed

2019 Cochrane

5. Screening for Prostate Cancer*

has published a white paper to provide some guidance regarding periprocedural prophylaxis. Since prostate biopsies are also an important part of some active surveillance programs, understanding these risks and communicating them to patients is not only integral to informed consent for prostate cancer screening but also for consideration of treatment options. Once diagnosed with prostate cancer, a man is faced with the risk of overtreatment of indolent disease due to the assumption that diagnosis (...) with a malignancy must necessarily result in treatment of this malignancy. Estimates of overdiagnosis vary widely from less than 5% to more than 75% depending upon the population used with lead times of 5 to 15 years. Although prostate cancer specific mortality and the need for related palliative care is decreased by screening, quality of life may be impaired as a result due to lasting impairment in urinary, bowel, and sexual function. There is considerable distress involved in the decision making process

2018 National Guideline Clearinghouse (partial archive)

7. Prostate Cancer

of malignant tumors. UICC International Union Against Cancer. 8th edn. 2017. 73. Cooperberg, M.R., et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol, 2005. 173: 1938. 74. Epstein, J.I., et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol, 2005. 29: 1228 (...) as predictors for prostate cancer. J Clin Oncol, 2009. 27: 398. 133. Stephan, C., et al. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer, 1997. 79: 104. 134. Catalona, W.J., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA, 1998. 279: 1542. 135

2018 European Association of Urology

8. PSA Testing and Early Management of Test-Detected Prostate Cancer

to be followed. Monitor more closely men with abnormal findings on pre-biopsy digital rectal examination, and those whose biopsy findings included either atypical small acinar proliferation or high-grade prostatic intra-epithelial neoplasia. In addition to further PSA testing and digital rectal examination, consider prostate imaging with investigations that can help to localise the site of cancer within the prostate, and repeat biopsy using a targeted approach. EBR (D) 3.2 8.1, 8.2xiii SUMMARY OF CLINICAL (...) men per 1000 at a cost of 230 unnecessary biopsies per 1,000 men tested; and with testing at 55-70 years and a testing interval of 1 year, the reduction in metastatic disease at diagnosis was 2.6 men per 1,000 at a cost of 185 unnecessary biopsies per 1000 men tested. Expressed in approximately equivalent terms to those of Table 2.3, increasing the frequency of testing from four- yearly to yearly increases the probability that diagnosis with metastatic prostate cancer is prevented by 0.06

2015 Cancer Council Australia

9. Prostate cancer screening with prostate-specific antigen (PSA) test Full Text available with Trip Pro

imaging (MRI), bone scan, and computed tomography, are often also performed, especially in men presenting with higher risk disease, to check for disease spread. Screening controversy For many reasons, PSA screening remains controversial. Advocates often base their opinions on the European Randomised study of Screening for Prostate Cancer (ERSPC), which suggests that screening may reduce the long term risk of prostate cancer-specific mortality by at least 9% (relative reduction). They also note (...) that substantial observational evidence indicates a reduction in advanced disease and reduction in prostate cancer mortality, which they attribute to the introduction of PSA screening. Opponents of PSA screening highlight the indolent natural course of prostate cancer, citing systematic reviews that reported little or no impact of PSA screening on overall and prostate cancer-specific mortality. Opponents also suggest that the harms and burden from overdiagnosis and overtreatment resulting in unnecessary

2018 BMJ Rapid Recommendations

10. High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer

the disease, while preserving continence and, if possible, potency [1] (B0001). Radiation therapy (RT) is another definitive treatment strategy in which a therapeutic dose of radi- ation is delivered to the tumour (either as external beam, brachytherapy, or a combination of both) while minimising the radiation to normal tissue. External beam RT (EBRT) utilises an external source of radiation to treat the prostate gland and a margin of adjacent normal tissue. Brachy- therapy directly implants a radioactive (...) source within the prostate, thus providing the highest dose of radiation. Its aim is to maximise irradiation of the tumour while minimising radiation to normal tissue [11] (B0001). Health problem PCa is the most common non-skin cancer in men in Europe [1]. Localised PCa is often indolent, and has no impact on health, even without treatment [12-14] (A0002). The incidence of PCa is higher in Northern and Western Europe compared with other areas of Europe, whereas incidence rates in Eastern and Southern

2018 EUnetHTA

11. Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines

Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines | CADTH.ca Find the information you need Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Prostate-Specific Antigen Testing for Prostate Cancer: Clinical Utility and Guidelines Last updated: August 22, 2019 Project Number: RA1060-000 Product Line: Research Type: Devices and Systems (...) Report Type: Reference List Result type: Report Question What is the clinical utility of prostate-specific antigen testing for prostate cancer? What are the evidence-based guidelines on the use of prostate-specific antigen testing for prostate cancer screening? Key Message Two systematic reviews were identified regarding the clinical utility of prostate-specific antigen testing for prostate cancer. In addition, five evidence-based guidelines were identified regarding the use of prostate-specific

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

12. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. Full Text available with Trip Pro

trends.MarketScan claims, which capture >30 million privately insured patients in the United States, were queried for all men aged 40-64 years for the years 2008-2014. PSA testing, prostate biopsy, prostate cancer diagnosis, and definitive local treatment were determined using associated International Classification of Diseases, Ninth Revision and Current Procedural Terminology, Fourth Edition codes.There were approximately 6 million qualifying men with a full year of data. PSA testing, prostate biopsy (...) PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. The 2012 United States Preventive Services Task Force recommendation against screening for prostate cancer has impacted rates of prostate-specific antigen (PSA) screening and appears to be associated with declining prostate cancer incidence. Our objective was to characterize health care utilization that may explain these observed

2018 Cancer

13. Prostate-Specific Antigen (PSA)?based population screening for prostate cancer: an evidence-based analysis

Prostate-Specific Antigen (PSA)?based population screening for prostate cancer: an evidence-based analysis Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis Pron G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Pron G. Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis. Toronto: Health Quality Ontario (HQO). Ontario Health Technology Assessment Series; 15(10). 2015 Authors' conclusions None of the systematic reviews of the randomized controlled screening trials for PC found a statistically significant reduction in relative risk of PC mortality or overall mortality with PSA-based population screening programs

2015 Health Technology Assessment (HTA) Database.

14. Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer

Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers - Health Technology Wales > Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers Topic Status (...) Incomplete Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer. Outcome of the appraisal The adoption of 68 Ga prostate-specific membrane antigen (PSMA) positron emission tomography (PET) for the diagnosis of recurrent prostate cancer is partially supported by the evidence. The use of 68 Ga PSMA PET provides a high degree of diagnostic accuracy on which to base management decisions as compared

2019 Health Technology Wales

15. Prostate Cancer

-staging 29 5.3.3.1 Alkaline phosphatase 29 5.3.3.2 Bone scan 29 5.3.4 New imaging modalities 29 5.3.4.1 Nodal metastases 29 5.3.4.2 Bone metastasis 30 5.3.5 Guidelines for staging of prostate cancer 30 6. DISEASE MANAGEMENT 30 6.1 Treatment: Deferred treatment (active surveillance/watchful waiting) 30 6.1.1 Introduction 30 6.1.1.1 Definition 30 6.1.1.1.1 Active surveillance 30 6.1.1.1.2 Watchful waiting 31 6.1.2 Deferred treatment of localised PCa (stage T1/T2, Nx/N0, M0) 31 6.1.2.1 Active (...) advanced Conclusions and recommendations have been rephrased and added to throughout the current document. Changed or new conclusions and recommendations can be found in sections: 5.2.4.3 Guidelines for imaging LE GR When clinical suspicion of PCa persists in spite of negative biopsies, MRI-targeted biopsies are recommended. 2b B10 PROSTATE CANCER - UPDATE MARCH 2015 Table 5.2.4: Recommended terminology for reporting prostate biopsies [3] • Benign/negative for malignancy. If appropriate, include

2015 European Association of Urology

16. Screening for Prostate Cancer with Prostate-Specific Antigen (PSA) Testing PCO Full Text available with Trip Pro

for prostate cancer using prostate-specific antigen (PSA) testing. STATEMENT OF THE CLINICAL ISSUE Section: Prostate cancer is the second leading cause of cancer deaths among men in the United States, , with the estimated number of deaths exceeding 28,000 in 2012. The rationale for screening asymptomatic men for prostate cancer in the general population is the potential for reducing mortality rates through early detection of the disease. However, much controversy exists between the potential harms (...) will ultimately be diagnosed with low-risk disease, which may not have presented itself clinically over their lifetimes. For men with low-risk disease who seek treatment, it is not clear if the risk of dying as a result of prostate cancer, or any other cause, is reduced compared with men who chose active surveillance. , In the Swedish study in which men were randomly assigned to surgery or watchful waiting, cancer-specific survival was higher among men who underwent surgery. However, the study patients did

2012 American Society of Clinical Oncology Guidelines

17. Early Detection of Prostate Cancer

Early Detection of Prostate Cancer Prostate Cancer: Early Detection Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online Learning For Medical Students Exams/LLL (...) and Quality of Care Accreditations and Reporting Patient Education Early Detection of Prostate Cancer (2018) Published 2013; Reviewed and Validity Confirmed 2018 The clinical guideline on Early Detection of Prostate Cancer discusses the detection of disease at an early, pre-symptomatic stage through the use of screening tools, such as PSA. Early detection allows for more conservative management, if needed, via means such as active surveillance and watchful waiting. [pdf] Panel Members H. Ballentine Carter

2018 American Urological Association

18. Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Health Professional Version

to nutritional sources of calcium, such as dairy products. Although more than half of the U.S. population uses and mineral supplements (at an annual cost of over 11 billion dollars), few studies include supplement use in the association of disease risk, including prostate cancer or mortality rates.[ , ] (Refer to the summary on for more information.) Preclinical/Animal Studies In vitro studies were treated with bovine milk, almond milk, milk, casein, or in a 2011 study. Treatment with bovine milk resulted (...) the impact of dietary and calcium on prostate cancer growth in . The mice were with human prostate cancer cells and were randomly assigned to receive specific diets (e.g., high calcium/vitamin D or normal calcium/no vitamin D). The mice that received the normal calcium/vitamin D-deficient diet exhibited significantly greater ( P < .05) tumor volumes than did mice that received the other diets.[ ] Human Studies Epidemiologic studies Several studies have found an association between high intakes of calcium

2017 PDQ - NCI's Comprehensive Cancer Database

19. Clinical practice guidelines PSA Testing and Early Management of Test-Detected Prostate Cancer

Clinical practice guidelines PSA Testing and Early Management of Test-Detected Prostate Cancer Clinical practice guidelines PSA Testing and Early Management of Test-Detected Prostate Cancer - Cancer Guidelines Wiki Skip Links Personal tools Search Navigation Cancer Council guidelines Methodology Hosted cancer guidelines Adolescents and Young Adult (AYA) guidelines Prevention Policies Social links Page actions Cite this guideline Prostate Cancer Foundation of Australia and Cancer Council (...) Australia PSA Testing Guidelines Expert Advisory Panel. Clinical practice guidelines PSA Testing and Early Management of Test-Detected Prostate Cancer. Sydney: Cancer Council Australia. [Version URL: , cited 2019 Mar 29]. Available from: . National Health and Medical Research Council These guidelines (recommendations) in the web-version of this guideline were approved by the Chief Executive Officer of the National Health and Medical Research Council (NHMRC) on 2 November 2015 under section 14A

2016 Clinical Practice Guidelines Portal

20. Enzalutamide for hormone-relapsed non-metastatic prostate cancer

that there are fewer people with undetected metastases who would otherwise be labelled as having non- metastatic disease. NICE technology appraisal guidance already recommends enzalutamide for hormone-relapsed metastatic prostate cancer before and after treatment with docetaxel. This appraisal relates to using enzalutamide at an earlier point in the treatment pathway. The committee noted that NHS England's policy stipulates that either enzalutamide or abiraterone (another antiandrogen) is to be offered only once (...) stopping treatment may speed up metastasis. The clinical experts commented that bicalutamide and dexamethasone are sometimes used for hormone-relapsed non-metastatic disease, but that the evidence for their effectiveness is limited. The committee considered ADT to be the standard of care in patients with hormone-relapsed prostate cancer, and the relevant comparator in this appraisal. The compan The company's definition of high risk does not closely match what is considered high y's definition of high

2019 National Institute for Health and Clinical Excellence - Technology Appraisals